# Arcus Biosciences, Inc.: Phase 2 study completed, 169 enrolled (Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Arcus Biosciences, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer |
| NCT ID | NCT04736173 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer; Lung Cancer |
| Intervention types | drug |
| Target enrollment | 169 |
| Site countries | United States, Hong Kong, Malaysia, Philippines, South Africa, South Korea, Taiwan, Thailand, Turkey (Türkiye), Vietnam |
| Posted | 2021-02-03 |
| Planned start | 2021-02-08 |
| Event | Completed |
| Event date | 2026-09-17 |
| Last update posted | 2026-10-19 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.
- 169 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04736173). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.